Adjuvant for Vaccine Immunotherapy of Cancer - Focusing on Toll-Like Receptor 2 and 3 Agonists for Safely Enhancing Antitumor Immunity

Cancer Science - United States
doi 10.1111/cas.12824
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Toll-Like Receptor-4 Modulation for Cancer Immunotherapy

Frontiers in Immunology
AllergyImmunology
2014English

Monoacyl Lipopeptide Agonist of Toll-Like Receptor 2 (TLR2) as a Vaccine Adjuvant

Science-Business eXchange
2013English

Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice

Clinical Cancer Research
Cancer ResearchOncology
2009English

Harnessing the Immune System to Fight Cancer With Toll-Like Receptor and RIG-I-like Receptor Agonists

Pharmacological Research
Pharmacology
2020English

Toll-Like Receptor 4 (TLR4) and TLR7 Ligands on Nanoparticles for Long-Lasting Immunity

Science-Business eXchange
2011English

Enhancing Cancer Immunotherapy via Activation of Innate Immunity

Seminars in Oncology
OncologyHematology
2015English

Sensing of Viral Infection and Activation of Innate Immunity by Toll-Like Receptor 3

Clinical Microbiology Reviews
ImmunologyEnvironmentalPublic HealthMicrobiologyMicrobiology EpidemiologyInfectious DiseasesOccupational Health
2008English

Toll-Like Receptor 2 (TLR2)

Science-Business eXchange
2009English

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists

Frontiers in Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy